A 65-year-old man with malignant chondroid syringoma (MCS) was found to have pulmonary metastases in the form of multiple pulmonary nodules 4 years after wide excision and adjuvant radiotherapy of a primary abdominal wall tumor. Atelectasis of the lingula due to obstructive endobronchial metastasis, resistant to combination chemotherapy, led us to perform high-dose rate (HDR) endobronchial brachytherapy for the first time in this rare tumor with a favorable response. This case emphasizes the role of HDR brachytherapy as a palliative procedure in endobronchial tumors not responding to other treatment modalities, even those considered to be radioresistant.

Hirsch P, Helwig EB: Chondroid syringoma: Mixed tumor of the skin salivary gland type. Arch Dermatol 1961;84:177–189.
Metzler G, Schaumburg-Lever G, Hornstein O, Rassner G: Malignant chondroid syringoma. Am J Dermatol 1996;18:83–89.
Shvilli D, Rothem A: Fulminant metastasizing chondroid syringoma of the skin. Am J Dermatol 1986;8:321–325.
Yamazaki N: Chemotherapy for advanced carcinoma of the skin: Experience with combination therapy and a review of the literature. Gan to Kagaku Ryoho 1997;24:30–36.
Steinmetz JC, Russo BA, Ginsburg RE: Malignant chondroid syringoma with widespread metastasis. J Am Acad Dermatol 1990;5:845–847.
Pisch J, Villamena PC, Rosenblatt E, Mishra S, Beattie EJ: HDR endobronchial irradiation in malignant airway obstruction. Chest 1993;104:721–725.
Spiser BL, Spralting I: Remote afterloading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys 1993;25:579–587.
Ishimura E, Iwamoto H, Kobashi Y, Yamabe H, Ichijima K: Malignant chondroid syringoma: Report of a case with widespread metastasis and review of the literature. Cancer 1983;52:1966–1973.
Dissanayake RVP, Salim R: Sweat gland carcinoma: Prognosis related to histological type. Histopathology 1980;4:445–466.
Borradori L, Hertet R, Ballintunes M, Zala L: Metastatic eccrine sweat gland carcinoma: Case report. Dermatologica 1988;177:295–299.
Kiely JL, Dunne B, McCabe M, McNicholas W: Malignant chondroid syringoma presenting as multiple pulmonary nodules. Thorax 1997;52:395–396.
Matz LR, McCully DJ, Stokes BAR: Metastasizing chondroid syringoma: Case report. Pathology 1969;1:77–81.
Redono C, Rocamora A, Villoria F, Garcia M: Malignant mixed tumor of the skin: Malignant chondroid syringoma. Cancer 1982;42:1690–1696.
Demoreas HP, Herrera GA, Mendonca AMN, et al: Metastatic malignant mixed tumor of the skin: Ultrastructural and immunocytochemical characterization, histogenic considerations, and comparison with benign mixed tumors of the skin and salivary glands. Appl Pathol 1986;4:199–208.
Paradelo JC, Waxman MJ, Throne BJ: Endobronchial irradiation with 192Ir in the treatment of malignant endobronchial obstruction. Chest 1992;102:1072–1074.
Mehta MP, Petereit DG, Chosy L, et al: Sequential comparison of low dose – rate and hyperfractionated high dose – rate endobronchial radiation for malignant airway occlusion. Int J Radiat Oncol Biol Phys 1992;23:133–139.
Vergnon JM: Which treatment for inoperable obstructive lung cancer; in Dumon JF (ed): Transatlantic Interventional Pulmonology Course. Marseille, 1996, pp 109–121.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.